glp-1 discontinuation rates ISPOR 2025: Exploring reasons for New Truveta study highlights patterns

A random effects model was selected to perform the meta-analyses, results were expressed as weighted mean differences for continuous outcomes and relative risks for dichotomous outcomes, both with 95% confidence intervals, and with I2 values and P values as markers of heterogeneity

The Trump administration announced a pricing model for popular GLP-1 drugs used to treat type 2 diabetes and obesity

The explosive demand for GLP-1 (glucagon-like peptide-1) receptor agonists, driven by their efficacy in treating obesity, has outpaced supply and created a dynamic market landscape

I wrote it as a mom who navigated recovery with my daughter after her AN diagnosis at 14, as a physician driven to understand this devastating illness, and as a biotech leader eager for new treatments

The relative risk of cholelithiasis was 1.2, 1.3, and 1.4 in liraglutide, dulaglutide, and semaglutide with number needed to harm of 17.25, 14.69, and 10.96, respectively

GLP-1 drugs like Ozempic linked to better mood in trials, says Dr